Comparative Analysis of ESBL Phenotypes and Antimicrobial Resistance in Escherichia coli Associated with Urinary Tract Infections and in Commensal Strains.
Denyss Guilcazo, Lazaro López, Diana Calderón, Katherine Vasquez, Cristina Chávez, Lance B Price, Jay P Graham, Joseph Eisenberg, Gabriel Trueba
{"title":"Comparative Analysis of ESBL Phenotypes and Antimicrobial Resistance in <i>Escherichia coli</i> Associated with Urinary Tract Infections and in Commensal Strains.","authors":"Denyss Guilcazo, Lazaro López, Diana Calderón, Katherine Vasquez, Cristina Chávez, Lance B Price, Jay P Graham, Joseph Eisenberg, Gabriel Trueba","doi":"10.1177/10766294251386346","DOIUrl":null,"url":null,"abstract":"<p><p><i>Escherichia coli</i> is a genetically versatile organism capable of thriving in diverse environments, acting as a commensal in the intestine or as a pathogen in the urinary tract. <i>E. coli</i> causing urinary tract infections has acquired genes that enable it to colonize the urinary tract, survive immune response, and resist antimicrobials. In this study, we investigated the association between the ESBL (Extended Spectrum Beta Lactamase) phenotype and other antimicrobial resistances in <i>E. coli</i> associated with urinary tract infections (UTI-<i>E. coli</i>; <i>n</i> = 1,139) and compared them with commensal <i>E. coli</i> strains (<i>n</i> = 405) isolated from human fecal samples in the same communities and during the same period. Among UTI-<i>E. coli</i> strains, 16.9% were ESBL producers compared to 7.6% in commensal strains, and resistance to other antimicrobials was also significantly higher in UTI-<i>E. coli</i>. These results suggest that many UTI-<i>E. coli</i> and commensal <i>E. coli</i> lineages have been subjected to distinct antimicrobial pressures over time.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial drug resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10766294251386346","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Escherichia coli is a genetically versatile organism capable of thriving in diverse environments, acting as a commensal in the intestine or as a pathogen in the urinary tract. E. coli causing urinary tract infections has acquired genes that enable it to colonize the urinary tract, survive immune response, and resist antimicrobials. In this study, we investigated the association between the ESBL (Extended Spectrum Beta Lactamase) phenotype and other antimicrobial resistances in E. coli associated with urinary tract infections (UTI-E. coli; n = 1,139) and compared them with commensal E. coli strains (n = 405) isolated from human fecal samples in the same communities and during the same period. Among UTI-E. coli strains, 16.9% were ESBL producers compared to 7.6% in commensal strains, and resistance to other antimicrobials was also significantly higher in UTI-E. coli. These results suggest that many UTI-E. coli and commensal E. coli lineages have been subjected to distinct antimicrobial pressures over time.
期刊介绍:
Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports.
MDR coverage includes:
Molecular biology of resistance mechanisms
Virulence genes and disease
Molecular epidemiology
Drug design
Infection control.